Magnificamide, a β-defensin-like peptide from the mucus of the sea anemone Heteractis magnifica, is a strong inhibitor of mammalian α-amylases
Sintsova, O.; Kalinovskii, A.; Gladkikh, I.; Zelepuga, E.; Monastyrnaya, M.; Kim, N.; Shevchenko, L.; Peigneur, S.; Tytgat, J.; Kozlovskaya, E.; Leychenko, E. (2019). Magnificamide, a β-defensin-like peptide from the mucus of the sea anemone Heteractis magnifica, is a strong inhibitor of mammalian α-amylases. Mar. Drugs 17(10): 542. https://dx.doi.org/10.3390/md17100542
In: Marine Drugs. Molecular Diversity Preservation International (MDPI): Basel. ISSN 1660-3397; e-ISSN 1660-3397, meer
|   |
| Trefwoorden |
Cnidaria [WoRMS]
Marien/Kust |
| Author keywords |
Cnidaria; sea anemones; venom; amylase inhibitors; defensin; diabetes |
| Auteurs | | Top |
- Sintsova, O.
- Kalinovskii, A.
- Gladkikh, I.
- Zelepuga, E.
|
- Monastyrnaya, M.
- Kim, N.
- Shevchenko, L.
- Peigneur, S., meer
|
- Tytgat, J., meer
- Kozlovskaya, E.
- Leychenko, E.
|
| Abstract |
Sea anemones’ venom is rich in peptides acting on different biological targets, mainly on cytoplasmic membranes and ion channels. These animals are also a source of pancreatic α-amylase inhibitors, which have the ability to control the glucose level in the blood and can be used for the treatment of prediabetes and type 2 diabetes mellitus. Recently we have isolated and characterized magnificamide (44 aa, 4770 Da), the major α-amylase inhibitor of the sea anemone Heteractis magnifica mucus, which shares 84% sequence identity with helianthamide from Stichodactyla helianthus. Herein, we report some features in the action of a recombinant analog of magnificamide. The recombinant peptide inhibits porcine pancreatic and human saliva α-amylases with Ki’s equal to 0.17 ± 0.06 nM and 7.7 ± 1.5 nM, respectively, and does not show antimicrobial or channel modulating activities. We have concluded that the main function of magnificamide is the inhibition of α-amylases; therefore, its functionally active recombinant analog is a promising agent for further studies as a potential drug candidate for the treatment of the type 2 diabetes mellitus. |
|
